Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMS-03305293 + temozolomide in recurrent glioblastoma
2023-508318-41-00Phase 2Suspended
- Sponsor
- Nerviano Medical Sciences
- Start
- Dec 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of itareparib and temozolomide in glioblastoma (GBM), diffuse astrocytoma, Oligodendroglioma (OG) and 1 more, sponsored by Nerviano Medical Sciences. Primary endpoints: First cycle Dose Limiting Toxicities (DLTs) and Objective Response Rate (ORR). Started Dec 2023; status: suspended.
02
Drugs
itareparibtemozolomide
03
Conditions
glioblastoma (GBM)diffuse astrocytomaOligodendroglioma (OG)glioma
Beyond the preview
Go deeper on 2023-508318-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508318-41-00.